Japan approves iron deficiency drug from Pharmacosmos

With the approval from the Japanese health authorities, Danish pharmaceutical firm Pharmacosmos can now initiate the launch of its iron deficiency anemia treatment in Japan.

Photo: Pharmacosmos / PR

Five years after Danish Pharmacosmos entered a strategic collaboration with Japanese partner Nippon Shinyaku on the launch of Monover (ferric derisomaltose) in Japan, the two parties can now initiate the marketing efforts in the country.

On Monday, the Japanese health authorities have cleared Monover in Japan, the company has announced in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs